A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome

Authors

  • Doruk Erkan,

    Corresponding author
    1. Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York
    • Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021
    Search for more papers by this author
    • Dr. Erkan has received speaking fees and/or honoraria for his service on the Genentech Advisory Board and the Human Genome Sciences/GlaxoSmithKline Speakers Bureau (less than $10,000 each) and has received a research grant from Genentech.

  • JoAnn Vega,

    1. Hospital for Special Surgery, New York, New York
    Search for more papers by this author
  • Glendalee Ramón,

    1. Hospital for Special Surgery, New York, New York
    Search for more papers by this author
  • Elizabeth Kozora,

    1. National Jewish Medical and Research Institute and University of Colorado Denver Medical School, Denver, and Hospital for Special Surgery, New York, New York
    Search for more papers by this author
  • Michael D. Lockshin

    1. Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery and Weill Medical College of Cornell University, New York, New York
    Search for more papers by this author

  • ClinicalTrials.gov identifier: NCT00537290.

Abstract

Objective

The primary objective of this study was to evaluate the safety of rituximab in antiphospholipid antibody (aPL)–positive patients with non-criteria manifestations of antiphospholipid syndrome (APS). The secondary objectives were to evaluate the effect of rituximab on the aPL profile and to evaluate the efficacy of rituximab treatment for non-criteria manifestations of APS.

Methods

In this 12-month, phase II pilot study, adult aPL-positive patients with thrombocytopenia, cardiac valve disease, skin ulcer, aPL nephropathy, and/or cognitive dysfunction received 2 doses of rituximab (1,000 mg) on days 1 and 15. Antiphospholipid antibody profiles and clinical outcome measures, which were categorized as complete response, partial response, no response, or recurrence, were analyzed at preset time points.

Results

Two of 19 patients experienced infusion reactions, resulting in early termination. Twelve serious adverse events and 49 nonserious adverse events were recorded. All patients who had positive results of lupus anticoagulant, anticardiolipin, and anti–β2-glycoprotein I antibody tests at baseline had positive results at 24 weeks and 52 weeks. The numbers of patients with a complete response, a partial response, no response, and recurrence for the clinical outcome measures at 24 weeks were as follows: for thrombocytopenia, 1, 1, 2, and 0, respectively; for cardiac valve disease, 0, 0, 3, and not analyzed, respectively; for skin ulcer, 3, 1, 0, and 1, respectively; for aPL nephropathy, 0, 1, 0, and 0, respectively; and for cognitive dysfunction, 3, 1, 1, and not analyzed, respectively.

Conclusion

The results of this uncontrolled and nonrandomized pilot study suggest that the safety of rituximab in aPL-positive patients is consistent with the safety profile of rituximab. Despite causing no substantial change in aPL profiles, rituximab may be effective in controlling some but not all non-criteria manifestations of APS.

Ancillary